|
1
|
The (Pro)renin receptor: site-specific and functional linkage to the vacuolar H+-ATPase in the kidney.
|
Hypertension
|
2009
|
2.47
|
|
2
|
Demographics and concomitant disorders in heart failure.
|
Lancet
|
2003
|
2.30
|
|
3
|
Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.
|
J Am Soc Nephrol
|
2005
|
1.96
|
|
4
|
The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy.
|
Can J Cardiol
|
2012
|
1.86
|
|
5
|
The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension.
|
Can J Cardiol
|
2013
|
1.85
|
|
6
|
Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions.
|
Proc Natl Acad Sci U S A
|
2007
|
1.82
|
|
7
|
Protein kinase Cbeta inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointerstitial injury in advanced experimental diabetic nephropathy.
|
J Am Soc Nephrol
|
2005
|
1.67
|
|
8
|
Mast cell infiltration and chemokine expression in progressive renal disease.
|
Kidney Int
|
2003
|
1.61
|
|
9
|
Urotensin II: a new player in vascular and myocardial disease?
|
Clin Sci (Lond)
|
2003
|
1.59
|
|
10
|
The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.
|
Can J Cardiol
|
2010
|
1.44
|
|
11
|
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy.
|
Can J Cardiol
|
2009
|
1.42
|
|
12
|
The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy.
|
Can J Cardiol
|
2011
|
1.38
|
|
13
|
Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group.
|
Can J Cardiol
|
2011
|
1.24
|
|
14
|
Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders.
|
J Hypertens
|
2007
|
1.23
|
|
15
|
Expression, localization, and function of the thioredoxin system in diabetic nephropathy.
|
J Am Soc Nephrol
|
2009
|
1.22
|
|
16
|
The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in humans and mice.
|
J Clin Invest
|
2012
|
1.18
|
|
17
|
Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy.
|
Circ Res
|
2003
|
1.18
|
|
18
|
Inhibition of platelet-derived growth factor promotes pericyte loss and angiogenesis in ischemic retinopathy.
|
Am J Pathol
|
2004
|
1.18
|
|
19
|
Hypertension in people with type 2 diabetes: Update on pharmacologic management.
|
Can Fam Physician
|
2011
|
1.17
|
|
20
|
Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism.
|
Am J Pathol
|
2011
|
1.17
|
|
21
|
Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy.
|
Circ Heart Fail
|
2009
|
1.16
|
|
22
|
COX-2 inhibition and retinal angiogenesis in a mouse model of retinopathy of prematurity.
|
Invest Ophthalmol Vis Sci
|
2003
|
1.16
|
|
23
|
Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension.
|
Diabetes
|
2003
|
1.15
|
|
24
|
Culture-modified bone marrow cells attenuate cardiac and renal injury in a chronic kidney disease rat model via a novel antifibrotic mechanism.
|
PLoS One
|
2010
|
1.13
|
|
25
|
Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy.
|
Nephrology (Carlton)
|
2011
|
1.12
|
|
26
|
Expression of the slit-diaphragm protein, nephrin, in experimental diabetic nephropathy: differing effects of anti-proteinuric therapies.
|
Nephrol Dial Transplant
|
2002
|
1.11
|
|
27
|
High glucose-induced thioredoxin-interacting protein in renal proximal tubule cells is independent of transforming growth factor-beta1.
|
Am J Pathol
|
2007
|
1.10
|
|
28
|
Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials.
|
Am Heart J
|
2003
|
1.10
|
|
29
|
PKC-beta1 mediates glucose-induced Akt activation and TGF-beta1 upregulation in mesangial cells.
|
J Am Soc Nephrol
|
2009
|
1.07
|
|
30
|
Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-beta.
|
Cardiovasc Res
|
2005
|
1.04
|
|
31
|
Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction.
|
Am J Physiol Heart Circ Physiol
|
2010
|
1.03
|
|
32
|
Transforming growth factor-beta1 differentially mediates fibronectin and inflammatory cytokine expression in kidney tubular cells.
|
Am J Physiol Renal Physiol
|
2006
|
1.02
|
|
33
|
Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental diabetes.
|
Kidney Int
|
2004
|
1.02
|
|
34
|
TGF-beta1 induces IL-8 and MCP-1 through a connective tissue growth factor-independent pathway.
|
Am J Physiol Renal Physiol
|
2005
|
1.01
|
|
35
|
Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarction.
|
J Mol Cell Cardiol
|
2005
|
1.00
|
|
36
|
The renin-angiotensin system influences ocular endothelial cell proliferation in diabetes: transgenic and interventional studies.
|
Am J Pathol
|
2003
|
0.99
|
|
37
|
Progression of tubulointerstitial injury by osteopontin-induced macrophage recruitment in advanced diabetic nephropathy of transgenic (mRen-2)27 rats.
|
Nephrol Dial Transplant
|
2002
|
0.96
|
|
38
|
Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary).
|
Can J Cardiol
|
2011
|
0.96
|
|
39
|
Tranilast attenuates structural and functional aspects of renal injury in the remnant kidney model.
|
J Am Soc Nephrol
|
2004
|
0.95
|
|
40
|
Effects on protein kinase C-beta inhibition on glomerular vascular endothelial growth factor expression and endothelial cells in advanced experimental diabetic nephropathy.
|
Am J Physiol Renal Physiol
|
2007
|
0.95
|
|
41
|
High glucose transactivates the EGF receptor and up-regulates serum glucocorticoid kinase in the proximal tubule.
|
Kidney Int
|
2005
|
0.95
|
|
42
|
Fluorescent microangiography is a novel and widely applicable technique for delineating the renal microvasculature.
|
PLoS One
|
2011
|
0.94
|
|
43
|
Early-outgrowth bone marrow cells attenuate renal injury and dysfunction via an antioxidant effect in a mouse model of type 2 diabetes.
|
Diabetes
|
2012
|
0.94
|
|
44
|
The endothelium in diabetic nephropathy.
|
Semin Nephrol
|
2012
|
0.93
|
|
45
|
Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy.
|
Am J Kidney Dis
|
2004
|
0.91
|
|
46
|
Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction.
|
Diabetes Care
|
2002
|
0.89
|
|
47
|
Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy.
|
Am J Physiol Heart Circ Physiol
|
2007
|
0.89
|
|
48
|
Early outgrowth cells release soluble endocrine antifibrotic factors that reduce progressive organ fibrosis.
|
Stem Cells
|
2013
|
0.88
|
|
49
|
Hypertension revisited.
|
Can Fam Physician
|
2012
|
0.88
|
|
50
|
High glucose induces macrophage inflammatory protein-3 alpha in renal proximal tubule cells via a transforming growth factor-beta 1 dependent mechanism.
|
Nephrol Dial Transplant
|
2007
|
0.87
|
|
51
|
A study of VEGF and its receptors in two rat models of proteinuria.
|
Nephron Physiol
|
2004
|
0.86
|
|
52
|
DPP-4 inhibition attenuates cardiac dysfunction and adverse remodeling following myocardial infarction in rats with experimental diabetes.
|
Cardiovasc Ther
|
2013
|
0.86
|
|
53
|
FT011, a new anti-fibrotic drug, attenuates fibrosis and chronic heart failure in experimental diabetic cardiomyopathy.
|
Eur J Heart Fail
|
2012
|
0.86
|
|
54
|
Transforming growth factor-beta in human diabetic nephropathy: effects of ACE inhibition.
|
Diabetes Care
|
2006
|
0.86
|
|
55
|
Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats.
|
Kidney Int
|
2002
|
0.86
|
|
56
|
Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus.
|
J Clin Hypertens (Greenwich)
|
2014
|
0.86
|
|
57
|
STI-571 inhibits in vitro angiogenesis.
|
Biochem Biophys Res Commun
|
2003
|
0.86
|
|
58
|
SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity.
|
Invest Ophthalmol Vis Sci
|
2006
|
0.86
|
|
59
|
Fas-induced apoptosis is a feature of progressive diabetic nephropathy in transgenic (mRen-2)27 rats: attenuation with renin-angiotensin blockade.
|
Nephrology (Carlton)
|
2004
|
0.85
|
|
60
|
Intra-coronary high-dose CD34+ stem cells in patients with chronic ischemic heart disease: a 12-month follow-up.
|
Int J Cardiol
|
2005
|
0.85
|
|
61
|
Angiotensin II-induced proteinuria and expression of the podocyte slit pore membrane protein, nephrin.
|
Nephrol Dial Transplant
|
2004
|
0.84
|
|
62
|
Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial.
|
Diabetologia
|
2014
|
0.84
|
|
63
|
Vascular endothelial growth factor expression and glomerular endothelial cell loss in the remnant kidney model.
|
Nephrol Dial Transplant
|
2003
|
0.84
|
|
64
|
Evaluation and optimization of antifibrotic activity of cinnamoyl anthranilates.
|
Bioorg Med Chem Lett
|
2009
|
0.84
|
|
65
|
The differential regulation of Smad7 in kidney tubule cells by connective tissue growth factor and transforming growth factor-beta1.
|
Nephrology (Carlton)
|
2007
|
0.84
|
|
66
|
Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy.
|
Nephron Physiol
|
2003
|
0.83
|
|
67
|
The cardiac (pro)renin receptor is primarily expressed in myocyte transverse tubules and is increased in experimental diabetic cardiomyopathy.
|
J Hypertens
|
2011
|
0.83
|
|
68
|
Over-expression of platelet-derived growth factor in human diabetic nephropathy.
|
Nephrol Dial Transplant
|
2003
|
0.83
|
|
69
|
Cells expressing the stem cell factor receptor, c-kit, contribute to neoangiogenesis in diabetes.
|
Diab Vasc Dis Res
|
2005
|
0.83
|
|
70
|
Platelet-derived growth factor receptor transactivation mediates the trophic effects of angiotensin II in vivo.
|
Hypertension
|
2004
|
0.83
|
|
71
|
Aliskiren increases bradykinin and tissue kallikrein mRNA levels in the heart.
|
Clin Exp Pharmacol Physiol
|
2011
|
0.82
|
|
72
|
Angiogenic dysfunction in bone marrow-derived early outgrowth cells from diabetic animals is attenuated by SIRT1 activation.
|
Stem Cells Transl Med
|
2012
|
0.82
|
|
73
|
Macrophage infiltration and cellular proliferation in the non-ischemic kidney and heart following prolonged unilateral renal ischemia.
|
Nephron Physiol
|
2007
|
0.82
|
|
74
|
Protein kinase C-beta inhibition attenuates the progression of nephropathy in non-diabetic kidney disease.
|
Nephrol Dial Transplant
|
2009
|
0.81
|
|
75
|
Does vascular endothelial growth factor (VEGF) play a role in the pathogenesis of minimal change disease?
|
Nephrol Dial Transplant
|
2003
|
0.80
|
|
76
|
Renal ischemia-reperfusion increases endothelial VEGFR-2 without increasing VEGF or VEGFR-1 expression.
|
Kidney Int
|
2002
|
0.80
|
|
77
|
A new anti-fibrotic drug attenuates cardiac remodeling and systolic dysfunction following experimental myocardial infarction.
|
Int J Cardiol
|
2012
|
0.80
|
|
78
|
Risks and benefits of intensive blood pressure lowering in patients with type 2 diabetes.
|
CMAJ
|
2013
|
0.79
|
|
79
|
Prevention of cardiovascular disease: an evidence-based clinical aid 2004.
|
Med J Aust
|
2004
|
0.79
|
|
80
|
Chronic kidney disease in diabetes.
|
Can J Diabetes
|
2013
|
0.79
|
|
81
|
Dipeptidyl peptidase-4 inhibition improves left ventricular function in chronic kidney disease.
|
Clin Invest Med
|
2014
|
0.78
|
|
82
|
Expression of filtrin in human glomerular diseases.
|
Nephrol Dial Transplant
|
2007
|
0.78
|
|
83
|
Bone marrow cell therapies for endothelial repair and their relevance to kidney disease.
|
Semin Nephrol
|
2012
|
0.78
|
|
84
|
Effect of atorvastatin on cardiac remodelling and mortality in rats following hyperglycemia and myocardial infarction.
|
Int J Cardiol
|
2009
|
0.77
|
|
85
|
3',4'-Bis-difluoromethoxycinnamoylanthranilate (FT061): an orally-active antifibrotic agent that reduces albuminuria in a rat model of progressive diabetic nephropathy.
|
Bioorg Med Chem Lett
|
2013
|
0.77
|
|
86
|
Perindopril attenuates tubular hypoxia and inflammation in an experimental model of diabetic nephropathy in transgenic Ren-2 rats.
|
Nephrology (Carlton)
|
2008
|
0.76
|
|
87
|
Impaired cardiac anti-oxidant activity in diabetes: human and correlative experimental studies.
|
Acta Diabetol
|
2014
|
0.76
|
|
88
|
Renin inhibition: new potential for an old therapeutic target.
|
Hypertension
|
2005
|
0.75
|
|
89
|
Role of the eNOS-NO system in regulating the antiproteinuric effects of VEGF receptor 2 inhibition in diabetes.
|
Biomed Res Int
|
2013
|
0.75
|
|
90
|
Tranilast ameliorates experimental mesangial proliferative glomerulonephritis.
|
Nephron Exp Nephrol
|
2008
|
0.75
|
|
91
|
Letter by Connelly et al regarding article, "Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension".
|
Circulation
|
2008
|
0.75
|
|
92
|
Progressive diabetic nephropathy in the Ren-2 rat.
|
Am J Physiol Renal Physiol
|
2007
|
0.75
|
|
93
|
Novel risk factors for heart failure when the whole may be greater than the sum of its parts.
|
J Am Coll Cardiol
|
2009
|
0.75
|
|
94
|
Hyperglycemia and renal mass ablation synergistically augment albuminuria in the diabetic subtotally nephrectomized rat: implications for modeling diabetic nephropathy.
|
Nephron Extra
|
2012
|
0.75
|
|
95
|
Treatment of hypertension.
|
Can J Diabetes
|
2013
|
0.75
|
|
96
|
Protein kinase C β inhibition ameliorates experimental mesangial proliferative glomerulonephritis.
|
Nephrology (Carlton)
|
2011
|
0.75
|